{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:47:22Z","timestamp":1767084442298},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"6 Supplement","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Low-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg\/d) is widely used in the prevention of cardiovascular (CV) events based on the results of large-scale studies supporting a benefit. However, questions remain regarding the benefit-risk relationship in certain settings since long-term use of ASA is not devoid of risk. Incontrovertible evidence supports the benefits of ASA treatment, which exceed the risks, in patients who have had a previous CV event (myocardial infarction, stroke, unstable angina, or transient ischemic attack). Nonetheless, the question remains for those patients who have not had a previous event (primary prevention), where the risk of CV events is lower and, consequently, the absolute benefit is also lower than in patients who have a history of a CV event or its equivalent (secondary prevention). Recent evidence from large-scale\nclinical trials shows that administration of low-dose ASA is associated with a reduced risk of CV events with a corresponding small absolute increase in the risk of major bleeding (eg, gastrointestinal bleeding and hemorrhagic stroke). Although the benefit and the risk of low-dose ASA in primary prevention are numerically similar, the clinical consequences of an increased risk of bleeding and a decreased risk of a CV event may not be equivalent. If these data are applied to patients with higher levels of CV outcome risk, more patients may potentially benefit from aspirin use in primary prevention.<\/jats:p>","DOI":"10.12788\/jfp.0222","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T19:28:56Z","timestamp":1633375736000},"source":"Crossref","is-referenced-by-count":2,"title":["Primary Prevention of CVD with Aspirin: Benefits vs Risks"],"prefix":"10.12788","volume":"70","author":[{"family":"Weisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","container-title":["The Journal of Family Practice"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/jfp_hot_topics2021_0722_v3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T19:28:56Z","timestamp":1633375736000},"score":1,"resource":{"primary":{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/jfp_hot_topics2021_0722_v3.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":0,"journal-issue":{"issue":"6 Supplement","published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.12788\/jfp.0222","relation":{},"subject":[],"published":{"date-parts":[[2021,7]]}}}